share_log

Hims & Hers Health (NYSE:HIMS) Delivers Shareholders Incredible 84% CAGR Over 3 Years, Surging 9.6% in the Last Week Alone

Hims & Hers Health (NYSE:HIMS) Delivers Shareholders Incredible 84% CAGR Over 3 Years, Surging 9.6% in the Last Week Alone

Hims & HERS Health (紐交所:HIMS) 在過去三年爲股東帶來了驚人的84%的年複合增長率,僅在上週就上漲了9.6%。
Simply Wall St ·  01/28 17:39

We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. You won't get it right every time, but when you do, the returns can be truly splendid. Take, for example, the Hims & Hers Health, Inc. (NYSE:HIMS) share price, which skyrocketed 525% over three years. It's also good to see the share price up 37% over the last quarter. It really delights us to see such great share price performance for investors.

我們認爲,找到出色的多年贏家的可能性是激勵許多投資者的原因。你不可能每次都對,但當你成功時,回報可能會非常可觀。以Hims & HERS Health, Inc.(紐交所:HIMS)的股價爲例,三年來股價飆升了525%。在過去的一個季度中,股價也上漲了37%。看到投資者獲得如此優異的股價表現,我們感到非常高興。

On the back of a solid 7-day performance, let's check what role the company's fundamentals have played in driving long term shareholder returns.

在強勁的7天表現的基礎上,讓我們來看看該公司基本面在推動長期股東回報中發揮了什麼作用。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

在他的文章《Graham-and-Doddsville超級投資者》中,禾倫·巴菲特描述了股價並不總是理性反映業務價值的情況。一個有缺陷但合理的評估公司情緒變化的方法是將每股收益(EPS)與股價進行比較。

During three years of share price growth, Hims & Hers Health moved from a loss to profitability. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

在三年的股價增長中,Hims & HERS Health從虧損轉向盈利。這種轉變可以成爲一個拐點,從而爲強勁的股價上漲提供了理由,正如我們在這裏看到的那樣。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下面的圖像中查看每股收益隨時間的變化(單擊圖表查看確切值)。

big
NYSE:HIMS Earnings Per Share Growth January 28th 2025
紐交所:HIMS 每股收益增長 2025年1月28日

It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

看到在過去三個月內有一些顯著的內部購買,是件好事。這是一個積極的信號。不過,我們認爲每股收益和營業收入增長的趨勢是更重要的考慮因素。在買入或賣出股票之前,我們總是建議對歷史增長趨勢進行仔細審查,詳情請見這裏。

A Different Perspective

不同的視角

It's good to see that Hims & Hers Health has rewarded shareholders with a total shareholder return of 238% in the last twelve months. That gain is better than the annual TSR over five years, which is 25%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Hims & Hers Health better, we need to consider many other factors. Take risks, for example - Hims & Hers Health has 2 warning signs we think you should be aware of.

看到Hims & HERS Health在過去12個月中以總股東回報238%的表現來回饋股東,真是令人高興。這個收益超過了五年的年化總股東回報率25%。因此,看來最近市場對公司的情緒是積極的。持樂觀態度的人可能會將最近股東回報率的改善視爲業務本身隨着時間的推移而改善的跡象。長期跟蹤股價表現總是很有趣。但要更好地理解Hims & HERS Health,我們需要考慮許多其他因素。例如風險 - Hims & HERS Health有2個警示信號,我們認爲你應該注意。

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

還有很多其他公司內部人士正在買入股票。你可能不想錯過這份內部人士正在購買的被低估的小盤公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文中引用的市場回報反映了當前在美國交易所上市股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 3501

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。